Trials / Completed
CompletedNCT01318902
Study of Oral Ixazomib in Adult Participants With Relapsed or Refractory Light Chain Amyloidosis
An Open-Label, Dose-Escalation, Phase 1 Study of the Oral Formulation of MLN9708 Administered Weekly in Adult Patients With Relapsed or Refractory Light-Chain (AL) Amyloidosis Who Require Further Treatment
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 27 (actual)
- Sponsor
- Millennium Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will include participants with previously treated systemic relapsed or refractory light-chain (AL) amyloidosis who require further therapy and will be aimed at determining the safety profile and the maximum tolerated dose/recommended phase 2 dose of MLN9078 (Ixazomib) administered orally.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ixazomib | Ixazomib capsules. |
| DRUG | Dexamethasone | Dexamethasone tablets. |
Timeline
- Start date
- 2011-04-27
- Primary completion
- 2018-11-13
- Completion
- 2018-11-13
- First posted
- 2011-03-21
- Last updated
- 2020-04-01
- Results posted
- 2020-04-01
Locations
10 sites across 5 countries: United States, Canada, France, Germany, Italy
Source: ClinicalTrials.gov record NCT01318902. Inclusion in this directory is not an endorsement.